Organogenesis Holdings Inc. Class A (ORGO) Dividend History

Organogenesis Holdings Inc. Class A (ORGO) is a biotechnology company focused on developing and commercializing advanced regenerative medicine products. It specializes in tissue repair and wound management solutions derived from living cells and biological materials, aiming to improve outcomes in diverse medical fields such as surgical, wound care, and dental applications.

85 Dan Road, Canton, MA, 02021
Phone: 781-575-0775
Website: https://www.organogenesis.com

Dividend History

Organogenesis Holdings Inc. Class A currently does not pay dividends

Company News

  • Organogenesis Holdings Inc. reported strong Q4 2024 revenue growth of 27%, driven by better-than-expected customer demand. However, the company expects a challenging operating environment in the first half of 2025 due to delays in the implementation of new Medicare coverage policies for skin substitute products. The company provided financial guidance for 2025 and updated on the progress of its ReNu clinical program.

    The Motley Fool
  • CANTON, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that management will participate in the Truist Securities MedTech Conference, which is being held at the InterContinental Boston in Boston, MA on Tuesday, June 18th. Management will participate in 1x1 meetings. There will be no formal presentation.

    GlobeNewswire Inc.
  • Organogenesis (ORGO) delivered earnings and revenue surprises of 100% and 6.45%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Investment Research
    Featured Companies: IPSC
  • Shares of Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) shares rose sharply during Wednesday’s session after Concentra sent an acquisition proposal to acquire 100% of equity of the company for $1.80 per share. Reneo Pharmaceuticals shares climbed 13.6% to $1.59 on Wednesday. Here are some other stocks moving in today's mid-day session. Gainers First Wave BioPharma, Inc. (NASDAQ: FWBI) shares jumped 169% to $9.90 after the company announced that it entered a non-binding term sheet to sell its Niclosamide program for the treatment of inflammatory bowel diseases. Cingulate Inc. (NASDAQ: CING) gained 95.2% to $4.08. RiskOn International, Inc. (NASDAQ: ROI) shares climbed 91.8% to $0.27. RiskOn International expects to announce its new generative AI platform and technology partner on Jan. 3, 2024. Cytokinetics, Incorporated (NASDAQ: CYTK) surged 64.2% to $75.05 after the company announced topline results from SEQUOIA-HCM, the Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy. AEye, Inc. (NASDAQ: LIDR) rose 61.2% to $3.58. Vince Holding Corp. (NYSE: VNCE) jumped 42% to $3.2399. Bit Brother Limited(NASDAQ: BETS) gained 38.2% to $0.0152 after jumping 111% on Tuesday. Nxu, Inc. (NASDAQ: NXU) rose 34% to $4.18. Virax Biolabs Group Limited (NASDAQ: VRAX) gained 32% to $1.7551. Jet.AI Inc. (NASDAQ: JTAI) shares gained 28% to $2.05 after falling 39% on Tuesday. Elicio Therapeutics, Inc. (NASDAQ: ELTX) jumped 25% to $8.89. Elicio Therapeutics 10% owner GKCC, LLC acquired a total of 1,213,000 shares an average price of $5.81. Matinas BioPharma Holdings, Inc. (NASDAQ: MTNB) gained 24.7% to ...

    Benzinga
  • Analysts say these are penny stocks to "buy" but do you agree? The post 7 Cheap Penny Stocks to Buy According To Analysts, Targets Up To 1,090% appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

    PennyStocks
    Featured Companies: BLDE RIGL RMTI
Page data last updated 07/23/2025 12:39:39 UTC